Boris Birmaher
University of Texas Southwestern Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Boris Birmaher.
Journal of the American Academy of Child and Adolescent Psychiatry | 2009
Benjamin I. Goldstein; Wael Shamseddeen; Anthony Spirito; Graham J. Emslie; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Benedetto Vitiello; Neal Ryan; Boris Birmaher; Taryn L. Mayes; Matthew Onorato; Jamies Zelazny; David A. Brent
OBJECTIVE Despite the known association between substance use disorders and major depressive disorder (MDD) among adolescents, little is known regarding substance use among adolescents with MDD. METHOD Youths with MDD who had not improved after an adequate selective serotonin reuptake inhibitor trial (N = 334) were enrolled in the Treatment of SSRI-Resistant Depression in Adolescents trial. Analyses examined substance use (via the Drug Use Severity Index) and changes therein in relation to treatment and depressive symptoms. Adolescents meeting substance use disorder criteria via the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version at baseline were excluded. RESULTS Substance use was common: 28.1% reported repeated experimentation at baseline. Substance-related impairment was associated with baseline depression severity, older age, physical/sexual abuse, family conflict, hopelessness, and comorbid oppositional defiant disorder/conduct disorder. There was significant improvement in substance-related impairment among adolescents who responded to MDD treatment. Baseline suicidal ideation was higher among the subjects who progressed to high substance-related impairment (≥ 75th percentile) versus those whose substance-related impairment remained low (< 75th percentile), and parental depressive symptoms predicted persistence of high substance-related impairment during the study. The MDD response was best among the adolescents with low 12 week substance-related impairment scores regardless of whether they had high or low baseline substance-related impairment. There were no significant differential effects of specific treatments, pharmacological or cognitive-behavioral therapy, on substance use. CONCLUSIONS Substance use is common among adolescents with treatment-resistant MDD. The subjects who had persistently low substance-related impairment or who demonstrated reduced substance-related impairment had better MDD treatment response, although the direction of this association is uncertain.
Archive | 2005
Robert A. Kowatch; Mary Fristad; Boris Birmaher; Karen Dineen Wagner; Robert L. Findling; Martha Hellander
Archive | 1996
David Brent; Claudia Roth; Diane Holder; David J. Kolko; Boris Birmaher; Barbara A. Johnson; Joy Schweers
Archive | 2002
Boris Birmaher; David Brent
Archive | 2010
Boris Birmaher; David Brent
Archive | 2012
David Brent; Boris Birmaher
Archive | 2016
Boris Birmaher; David Brent
Archive | 2014
Sarah McCue Horwitz; Eric A. Youngstrom; Thomas W. Frazier; Mary Fristad; Eugene L. Arnold; David Axelson; Boris Birmaher; Robert A. Kowatch; Robert L. Findling
Archive | 2009
Tina R. Goldstein; Boris Birmaher; David Axelson; Benjamin I. Goldstein; Mary Kay Gill; Christianne Esposito-Smythers; Neal D. Ryan; Michael Strober; Jeffrey Hunt; Martin B. Keller
Archive | 2006
Richard Rende; Boris Birmaher; David Axelson; Michael Strober; Mary Kay Gill; Sylvia Valeri; Laurel Chiappetta; Neal D. Ryan; Henrietta L. Leonard; Jeffrey Hunt; Satish Iyengar; Martin B. Keller